Compare TMP & SPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TMP | SPTX |
|---|---|---|
| Founded | 1836 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.1B |
| IPO Year | 1996 | 2026 |
| Metric | TMP | SPTX |
|---|---|---|
| Price | $100.99 | $23.78 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $87.00 | N/A |
| AVG Volume (30 Days) | 83.7K | ★ 93.2K |
| Earning Date | 04-24-2026 | N/A |
| Dividend Yield | ★ 3.21% | N/A |
| EPS Growth | ★ 126.16 | N/A |
| EPS | ★ 3.86 | N/A |
| Revenue | ★ $75,742,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $7.94 | N/A |
| P/E Ratio | $25.99 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $61.88 | $17.59 |
| 52 Week High | $102.02 | $24.65 |
| Indicator | TMP | SPTX |
|---|---|---|
| Relative Strength Index (RSI) | 61.77 | 66.31 |
| Support Level | $91.10 | $18.72 |
| Resistance Level | $102.02 | N/A |
| Average True Range (ATR) | 2.27 | 1.34 |
| MACD | -0.17 | 0.25 |
| Stochastic Oscillator | 81.69 | 84.35 |
Tompkins Financial Corp is a Financial Holding Company. The company manages its operations through two business segments, consisting of banking and wealth management. It offers various products and services, including commercial and consumer banking, leasing, trust and investment management, financial planning and wealth management, and insurance. Wealth management activities include the results of the company's trust, financial planning, and wealth management services. The company generates the majority of its revenue from the Banking segment.
Seaport Therapeutics Inc is a clinical-stage therapeutics company. The company focuses on invention and development of new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. The company identified clinically validated mechanisms with established efficacy and safety profiles, historically limited by high first-pass metabolism, low bioavailability, and side effects. The company's pipeline products are based on Glyph, company's lymphatic-targeting prodrug technology is designed to bypass first-pass metabolism and thereby enhance a drug's oral bioavailability and reduce side effects.